JP2019529554A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529554A5
JP2019529554A5 JP2019536698A JP2019536698A JP2019529554A5 JP 2019529554 A5 JP2019529554 A5 JP 2019529554A5 JP 2019536698 A JP2019536698 A JP 2019536698A JP 2019536698 A JP2019536698 A JP 2019536698A JP 2019529554 A5 JP2019529554 A5 JP 2019529554A5
Authority
JP
Japan
Prior art keywords
cancer
met
mutation
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529554A (ja
JP7065858B2 (ja
Filing date
Publication date
Priority claimed from GBGB1616116.8A external-priority patent/GB201616116D0/en
Application filed filed Critical
Publication of JP2019529554A publication Critical patent/JP2019529554A/ja
Publication of JP2019529554A5 publication Critical patent/JP2019529554A5/ja
Application granted granted Critical
Publication of JP7065858B2 publication Critical patent/JP7065858B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536698A 2016-09-22 2017-09-21 MET突然変異を宿すがんを治療するためのc-Met阻害剤の使用 Active JP7065858B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1616116.8 2016-09-22
GBGB1616116.8A GB201616116D0 (en) 2016-09-22 2016-09-22 Use of c-Met inhibitors to treat cancers harbouring MET mutations
PCT/EP2017/073894 WO2018055029A1 (en) 2016-09-22 2017-09-21 Use of c-met inhibitors to treat cancers harbouring met mutations

Publications (3)

Publication Number Publication Date
JP2019529554A JP2019529554A (ja) 2019-10-17
JP2019529554A5 true JP2019529554A5 (enExample) 2020-10-22
JP7065858B2 JP7065858B2 (ja) 2022-05-12

Family

ID=57539720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536698A Active JP7065858B2 (ja) 2016-09-22 2017-09-21 MET突然変異を宿すがんを治療するためのc-Met阻害剤の使用

Country Status (18)

Country Link
US (1) US20190282570A1 (enExample)
EP (1) EP3515418B1 (enExample)
JP (1) JP7065858B2 (enExample)
CN (1) CN109789108A (enExample)
CY (1) CY1124668T1 (enExample)
DK (1) DK3515418T3 (enExample)
ES (1) ES2880085T3 (enExample)
GB (1) GB201616116D0 (enExample)
HR (1) HRP20210998T1 (enExample)
HU (1) HUE054765T2 (enExample)
LT (1) LT3515418T (enExample)
PL (1) PL3515418T3 (enExample)
PT (1) PT3515418T (enExample)
RS (1) RS62084B1 (enExample)
SI (1) SI3515418T1 (enExample)
SM (1) SMT202100405T1 (enExample)
TW (1) TWI784969B (enExample)
WO (1) WO2018055029A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220008419A1 (en) * 2018-11-14 2022-01-13 Kanazawa Medical University Pharmaceutical composition for treating diffuse-type gastric cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK1959955T3 (da) * 2005-12-05 2011-02-07 Pfizer Prod Inc Fremgangsmåde til behandling af abnorm cellevækst
CN101415730B (zh) * 2006-03-30 2013-04-10 诺瓦提斯公司 c-Met抗体的组合物和使用方法
HUE025504T2 (en) 2009-12-31 2016-02-29 Hutchison Medipharma Ltd Certain triazolopyrazines, compositions thereof and methods of use therefor

Similar Documents

Publication Publication Date Title
JP2016163571A5 (enExample)
CR20210281A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
JP2015536964A5 (enExample)
JP2017506624A5 (enExample)
JP2016034978A5 (enExample)
RU2015121367A (ru) Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
JP2017504611A5 (enExample)
NZ714963A (en) Compositions and methods for treating anemia
JP2012515184A5 (enExample)
JP2019517542A5 (enExample)
JP2014525454A5 (enExample)
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2013541583A5 (enExample)
JP2019530706A5 (enExample)
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
JP2021504384A5 (enExample)
JP2020529995A5 (enExample)
JP2015507020A5 (enExample)
JP2005530735A5 (enExample)
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
JP2016505050A5 (enExample)
JP2021505669A5 (enExample)